Jongsma, Maria M E
Aardoom, Martine A
Cozijnsen, Martinus A
van Pieterson, Merel
de Meij, Tim
Groeneweg, Michael
Norbruis, Obbe F
Wolters, Victorien M
van Wering, Herbert M
Hojsak, Iva
Kolho, Kaija-Leena
Hummel, Thalia
Stapelbroek, Janneke
van der Feen, Cathelijne
van Rheenen, Patrick F
van Wijk, Michiel P
Teklenburg-Roord, Sarah T A
Schreurs, Marco W J
Rizopoulos, Dimitris
Doukas, Michail
Escher, Johanna C
Samsom, Janneke N
de Ridder, Lissy https://orcid.org/0000-0002-6035-1182
Clinical trials referenced in this document:
Documents that mention this clinical trial
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial
https://doi.org/10.1136/gutjnl-2020-322339
Documents that mention this clinical trial
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial
https://doi.org/10.1136/gutjnl-2020-322339
Funding for this research was provided by:
Zomw, the Netherlands Organisation for Health Research and Development (113202001)
Crocokids (NA)
Pfizer (Study ID WI213008)